Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DA 1726

Next Previous
X
Search
Drug Profile

DA 1726

Alternative Names: DA-1726

Latest Information Update: 08 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A ST
  • Developer Dong-A ST; NeuroBo Pharmaceuticals
  • Class Anorectics; Gastrointestinal hormones; Hepatoprotectants; Obesity therapies; Peptides
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 06 Aug 2024 NeuroBo Pharmaceuticals signs a joint research agreement with Dong-A ST and ImmunoForge, to develop a long-acting, once-monthly, formulation of DA 1726
  • 22 Jun 2024 Pharmacodynamics data from a preclinical trial in Obesity released by NeuroBo Pharmaceuticals
  • 12 Apr 2024 NeuroBo Pharmaceuticals plans phase-I trial for Obesity (In adults) in USA (SC) in the first half of 2024 (NCT06252220)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top